• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Healthpeak Properties Reports Fourth Quarter and Year Ended 2023 Results

    2/8/24 4:15:00 PM ET
    $BMY
    $PEAK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Real Estate Investment Trusts
    Real Estate
    Get the next $BMY alert in real time by email

    Healthpeak Properties, Inc. (NYSE:PEAK), a leading owner, operator, and developer of real estate for healthcare discovery and delivery, today announced results for the fourth quarter and full-year ended December 31, 2023.

    FOURTH QUARTER 2023 FINANCIAL PERFORMANCE AND RECENT HIGHLIGHTS

    – Net income of $0.13 per share, Nareit FFO of $0.48 per share, FFO as Adjusted of $0.46 per share, AFFO of $0.36 per share, and Total Same-Store Portfolio Cash (Adjusted) NOI growth of 3.6%

    – Fourth quarter new and renewal lease executions totaled 1.1 million square feet:

    • Outpatient Medical new and renewal lease executions totaled 743,000 square feet
    • Lab new and renewal lease executions totaled 312,000 square feet
    • Year-to-date 2024 Lab lease executions of 58,000 square feet with an additional 115,000 square feet under signed LOI

    – Received entitlements for an additional 1.3 million square feet of lab development at the Vantage campus in South San Francisco

    – Commenced two on-campus outpatient developments in our HCA Healthcare ("HCA") development program

    – Entered into a new $236 million joint venture through the sale of a 65% interest in the Callan Ridge lab campus in the Torrey Pines submarket of San Diego in January 2024

    – Net Debt to Adjusted EBITDAre was 5.2x for the quarter ended December 31, 2023

    FULL-YEAR 2023 HIGHLIGHTS

    – Net income of $0.56 per share, Nareit FFO of $1.79 per share, FFO as Adjusted of $1.78 per share, AFFO of $1.53 per share, and Total Same-Store Portfolio Cash (Adjusted) NOI growth of 4.8%

    – Portfolio leasing summary:

    • Full-year outpatient lease executions totaled 4.1 million square feet, with +4% cash releasing spreads on renewals
    • Full-year lab lease executions totaled 985,000 square feet, with +23% cash releasing spreads on renewals

    – Development highlights:

    • 2023 completions and new starts:
    • Nexus on Grand: Delivered the fully leased, 148,000 square foot, $161 million lab building in South San Francisco
    • Vantage: Delivered the fully leased, 154,000 square foot, $201 million first building of Phase I in South San Francisco
    • Callan Ridge: Completed core and shell work and delivered the space to the tenant for T.I. build out; the fully leased development in Torrey Pines totals 185,000 square feet with an expected total development cost of $146 million
    • HCA Development Program: Commenced construction on two new outpatient developments totaling 192,000 square feet with total expected development costs of $90 million
    • Land bank and future developments:
    • In September 2023, the Cambridge City Council unanimously approved a comprehensive rezoning to allow for greater density and developable heights in the West Cambridge neighborhood of Alewife where Healthpeak owns a total of 39 acres
    • In December 2023, Healthpeak received entitlements for an additional 1.3 million square feet of lab development at the Vantage campus

    – Issued $750 million of senior unsecured notes at blended yield of approximately 5.35% and weighted average initial maturity of approximately 10 years

    – Sold $130 million of non-core properties at an average trailing cash yield of 5.4% and received $205 million of seller financing and other loan repayments

    – 2023 sustainability and responsible business recognitions include:

    • Received a Green Star rating from the Global Real Estate Sustainability Benchmark (GRESB) and named a constituent in the FTSE4Good Index for the twelfth consecutive year
    • Named to CDP's Leadership band for the eleventh consecutive year, named a constituent in the S&P Global Dow Jones Sustainability N. America Index for the eleventh consecutive year and World Index for the fourth time; and named to the S&P Global Sustainability Yearbook for the ninth consecutive year
    • Named an ENERGY STAR Partner of the Year for the third time
    • Named to Newsweek's America's Most Responsible Companies list for the fifth consecutive year
    • Named Winner for Best Proxy Statement (Mid Cap), and Finalist for Best ESG Reporting (Small to Mid Cap) by IR Magazine and Governance Intelligence
    • Certified a Great Place to Work for the fourth consecutive year; included in The Tennessean Top Workplaces for the second consecutive year; and a Middle Tennessee Top Workplace for the first time
    • Included in Fortune's Best Workplaces in Real Estate list for the second consecutive year

    To learn more about Healthpeak's commitment to responsible business and view our 2022 ESG Report, please visit www.healthpeak.com/ESG.

    FOURTH QUARTER COMPARISON

     

    Three Months Ended December 31, 2023

     

    Three Months Ended December 31, 2022

    (in thousands, except per share amounts)

    Amount

     

    Per Share

     

    Amount

     

    Per Share

    Net income, diluted

    $

    70,787

     

    $

    0.13

     

    $

    6,388

     

    $

    0.01

    Nareit FFO, diluted

     

    263,810

     

     

    0.48

     

     

    192,158

     

     

    0.35

    FFO as Adjusted, diluted

     

    252,639

     

     

    0.46

     

     

    238,744

     

     

    0.44

    AFFO, diluted

     

    196,622

     

     

    0.36

     

     

    194,414

     

     

    0.36

    FULL-YEAR COMPARISON

     

    Year Ended

    December 31, 2023

     

    Year Ended

    December 31, 2022

    (in thousands, except per share amounts)

    Amount

     

    Per Share

     

    Amount

     

    Per Share

    Net income, diluted

    $

    304,284

     

    $

    0.56

     

    $

    497,792

     

    $

    0.92

    Nareit FFO, diluted

     

    994,574

     

     

    1.79

     

     

    904,573

     

     

    1.66

    FFO as Adjusted, diluted

     

    987,708

     

     

    1.78

     

     

    950,259

     

     

    1.74

    AFFO, diluted

     

    847,358

     

     

    1.53

     

     

    790,296

     

     

    1.45

    Nareit FFO, FFO as Adjusted, AFFO, Same-Store Cash (Adjusted) NOI, and Net Debt to Adjusted EBITDAre are supplemental non-GAAP financial measures that we believe are useful in evaluating the operating performance and financial position of real estate investment trusts (see the "Funds From Operations" and "Adjusted Funds From Operations" sections of this release for additional information). See "December 31, 2023 Discussion and Reconciliation of Non-GAAP Financial Measures" for definitions, discussions of their uses and inherent limitations, and reconciliations to the most directly comparable financial measures calculated and presented in accordance with GAAP in the Investor Relations section of our website at http://ir.healthpeak.com/quarterly-results.

    SAME-STORE ("SS") OPERATING SUMMARY

    The table below outlines the year-over-year three-month and full-year SS Cash (Adjusted) NOI growth.

    Year-Over-Year Total SS Portfolio Cash (Adjusted) NOI Growth

     

    Three Month

     

    Full Year

     

    SS Growth %

    % of SS

     

    SS Growth %

    % of SS

    Lab

    2.7

    %

    47.1

    %

     

    3.7

    %

    46.6

    %

    Outpatient Medical

    4.3

    %

    41.4

    %

     

    3.4

    %

    42.0

    %

    CCRC

    4.7

    %

    11.5

    %

     

    15.6

    %

    11.5

    %

    Total Portfolio

    3.6

    %

    100.0

    %

     

    4.8

    %

    100.0

    %

    CALLAN RIDGE LAB CAMPUS JOINT VENTURE SALE

    As previously announced, in January 2024, Healthpeak formed a new strategic joint venture with Breakthrough Properties ("Breakthrough") through a sale of a 65% interest in Healthpeak's fully leased Callan Ridge lab campus in the Torrey Pines submarket of San Diego.

    The formation of the 65% Breakthrough / 35% Healthpeak joint venture values Callan Ridge at $236 million, or $1,275 per square foot, and represents a stabilized cash capitalization rate of 5.3% based on the initial annual rental rate of approximately $67 per square foot. At closing, net proceeds to Healthpeak were approximately $130 million. Additionally, the formation of the joint venture reduces Healthpeak's future tenant improvement funding by approximately $20 million.

    Healthpeak began construction on the 185,000 square foot Callan Ridge campus in 2021. The two-building campus is fully leased to Turning Point Therapeutics, Inc., a subsidiary of Bristol-Myers Squibb Company (NYSE:BMY), through April 2035.

    DEVELOPMENT UPDATES

    VANTAGE ENTITLEMENTS

    As previously announced, in December 2023, Healthpeak received entitlements for an additional 1.3 million square feet of lab space at the Vantage campus, bringing the combined campus to approximately 1.7 million square feet upon full build out. The additional entitlements represent double the allowable density compared to when Healthpeak originally acquired the land. The long-term nature of the entitlements offers flexibility to deliver the balance of the development in phases to align with market demand.

    Strategically located in the heart of South San Francisco and at the doorstep of Genentech's headquarters, the 20-acre purpose-built lab campus offers tenants a highly amenitized, world-class campus setting with access to multiple modes of transportation including direct access to the Rails-to-Trails pathway, which provides a pedestrian connection to downtown South San Francisco's restaurant and retail corridor, as well as the Caltrain station, which recently completed a multi-year renovation.

    Healthpeak is South San Francisco's largest investor-owned landlord with a portfolio that encompasses 4.9 million square feet, including some the submarket's most desirable campuses including The Cove, Portside at Oyster Point, The Shore, Vantage, and Pointe Grand, among others.

    OUTPATIENT DEVELOPMENT PROGRAM WITH HCA

    During the fourth quarter, Healthpeak added two on-campus outpatient developments with total expected development costs of $90 million to its program with HCA.

    • Galen Aurora: 72,000 square foot Class A medical training facility located on HCA's Medical Center of Aurora hospital campus, a 325-bed acute care hospital in Denver, CO where Healthpeak currently owns three on-campus buildings totaling approximately 165,000 square feet. HCA nursing and professional education affiliates have pre-leased 100% of the development.
    • McKinney Medical Center: 120,000 square foot Class A outpatient building on the campus of HCA's Medical City McKinney campus, a 281-bed acute care hospital in McKinney, TX where Healthpeak currently owns two on-campus buildings totaling approximately 120,000 square feet. HCA affiliates have pre-leased approximately 62% of the development for future outpatient services, including oncology, orthopedic, cardiology, wound care, imaging, and other services.

    Since 2019, Healthpeak's development program with HCA has delivered 9 outpatient buildings totaling 785,000 square feet with total development costs of approximately $235 million and is under construction on an additional three buildings totaling 262,000 square feet with total expected development costs of $121 million.

    MERGER WITH PHYSICIANS REALTY TRUST AND TERM LOAN UPDATE

    As previously announced on October 30, 2023, Healthpeak and Physicians Realty Trust entered into a definitive agreement to combine in an all-stock merger of equals. Each company will hold its respective special meeting of stockholders on February 21, 2024. Subject to Physicians Realty Trust's stockholders approving the proposed merger and Healthpeak's stockholders approving the issuance of Healthpeak common stock in connection with the proposed merger, among other matters, as well as the satisfaction or waiver of customary closing conditions, the transaction is expected to close on March 1, 2024.

    Additionally, Healthpeak expects to enter into a new $750 million 5-year unsecured term loan. Proceeds from the term loan are expected to fund the repayment of $210 million of Physicians Realty Trust private placement notes and to be used for general corporate purposes, including transaction costs and repayment of borrowings under Healthpeak's credit facility and commercial paper program. Healthpeak has entered into forward-starting swap agreements to fix the interest rate of the new term loan at approximately 4.5% for the full 5-year term of the loan.

    DIVIDEND

    On January 31, 2024, Healthpeak's Board declared a quarterly common stock cash dividend of $0.30 per share to be paid on February 26, 2024, to stockholders of record as of the close of business on February 14, 2024.

    2024 OUTLOOK

    For full year 2024, we have established the following outlook ranges, which are inclusive of the impact from the Physicians Realty Trust merger:

    • Diluted earnings per common share of $0.07 – $0.13
    • Diluted Nareit FFO per share of $1.54 – $1.60
    • Diluted FFO as Adjusted per share of $1.73 – $1.79  
    • Diluted AFFO per share of $1.50 – $1.56
    • Total Portfolio Same-Store Cash (Adjusted) NOI growth of 2.25% – 3.75%

    This outlook assumes the merger with Physicians Realty Trust closes on March 1, 2024. These estimates are based on our view of existing market conditions, transaction timing, and other assumptions for the year ending December 31, 2024. Additionally, the outlook includes estimates for certain merger-related accounting adjustments, which will not be finalized until after the merger closes. For additional details and assumptions underlying this outlook, please see page 40 in our corresponding Supplemental Report and the Discussion and Reconciliation of Non-GAAP Financial Measures, both of which are available in the Investor Relations section of our website at http://ir.healthpeak.com.

    CONFERENCE CALL INFORMATION

    Healthpeak has scheduled a conference call and webcast for Friday, February 9, 2024, at 8:00 a.m. Mountain Time.

    The conference call can be accessed in the following ways:

    • Healthpeak's website: https://ir.healthpeak.com/news-events
    • Webcast: https://events.q4inc.com/attendee/292488797. Joining via webcast is recommended for those who will not be asking questions.
    • Telephone: The participant dial-in number is (800) 715-9871.

    An archive of the webcast will be available on Healthpeak's website through February 7, 2025, and a telephonic replay can be accessed through February 15, 2024, by dialing (800) 770-2030 and entering conference ID number 58822.

    ABOUT HEALTHPEAK

    Healthpeak Properties, Inc. is a fully integrated real estate investment trust (REIT) and S&P 500 company. Healthpeak owns, operates and develops high-quality real estate for healthcare discovery and delivery.

    FORWARD-LOOKING STATEMENTS

    Statements contained in this release that are not historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among other things, statements regarding our and our officers' intent, belief or expectation as identified by the use of words such as "may," "will," "project," "expect," "believe," "intend," "anticipate," "seek," "target," "forecast," "plan," "potential," "estimate," "could," "would," "should" and other comparable and derivative terms or the negatives thereof. Examples of forward-looking statements include, among other things: (i) statements regarding timing, outcomes and other details relating to current, pending or contemplated acquisitions, dispositions, transitions, developments, redevelopments, densifications, joint venture transactions, leasing activity and commitments, financing activities, or other transactions discussed in this release, including statements regarding our proposed merger with Physicians Realty Trust; (ii) the payment of a quarterly cash dividend; and (iii) the information presented under the heading "2024 Outlook." Pending acquisitions, dispositions, joint venture transactions, leasing activity, and financing activity, including those subject to binding agreements, remain subject to closing conditions and may not be completed within the anticipated timeframes or at all. Forward-looking statements reflect our current expectations and views about future events and are subject to risks and uncertainties that could significantly affect our future financial condition and results of operations. While forward-looking statements reflect our good faith belief and assumptions we believe to be reasonable based upon current information, we can give no assurance that our expectations or forecasts will be attained. Further, we cannot guarantee the accuracy of any such forward-looking statement contained in this release, and such forward-looking statements are subject to known and unknown risks and uncertainties that are difficult to predict. These risks and uncertainties include, but are not limited to: macroeconomic trends, including inflation, interest rates, labor costs, and unemployment; risks associated with the proposed merger transactions with Physicians Realty Trust (the "Mergers"), including, but not limited to, our ability to consummate the Mergers on the proposed terms or on the anticipated timeline, or at all, potential loss or disruption of current and prospective commercial relationships due to the uncertainties about the Mergers, and the outcome of legal proceedings instituted against us, our Board of Directors, and others related to the Mergers; our ability to integrate the operations of the Company and Physicians Realty Trust successfully and realize the anticipated synergies and other benefits of the Mergers or do so within the anticipated time frame; changes within the industries in which we operate; significant regulation, funding requirements, and uncertainty faced by our lab tenants; factors adversely affecting our tenants', operators', or borrowers' ability to meet their financial and other contractual obligations to us; the insolvency or bankruptcy of one or more of our major tenants, operators, or borrowers; our concentration of real estate investments in the healthcare property sector, which makes us more vulnerable to a downturn in a specific sector than if we invested across multiple sectors; the illiquidity of real estate investments; our ability to identify and secure new or replacement tenants and operators; our property development, redevelopment, and tenant improvement risks, including project abandonments, project delays, and lower profits than expected; the ability of the hospitals on whose campuses our outpatient medical buildings are located and their affiliated healthcare systems to remain competitive or financially viable; our ability to develop, maintain, or expand hospital and health system client relationships; operational risks associated with third party management contracts, including the additional regulation and liabilities of our properties operated through RIDEA structures; economic conditions, natural disasters, weather, and other conditions that negatively affect geographic areas where we have concentrated investments; uninsured or underinsured losses, which could result in significant losses and/or performance declines by us or our tenants and operators; our investments in joint ventures and unconsolidated entities, including our lack of sole decision making authority and our reliance on our partners' financial condition and continued cooperation; our use of fixed rent escalators, contingent rent provisions, and/or rent escalators based on the Consumer Price Index; competition for suitable healthcare properties to grow our investment portfolio; our ability to foreclose or exercise rights on collateral securing our real estate-related loans; any requirement that we recognize reserves, allowances, credit losses, or impairment charges; investment of substantial resources and time in transactions that are not consummated; our ability to successfully integrate or operate acquisitions; the potential impact on us and our tenants, operators, and borrowers from litigation matters, including rising liability and insurance costs; environmental compliance costs and liabilities associated with our real estate investments; ESG and sustainability commitments and requirements, as well as stakeholder expectations; epidemics, pandemics, or other infectious diseases, including Covid, and health and safety measures intended to reduce their spread; human capital risks, including the loss or limited availability of our key personnel; our reliance on information technology systems and the possibility of a cybersecurity incident or cybersecurity threat affect our information systems or the information systems of our tenants, operators or borrowers; volatility, disruption, or uncertainty in the financial markets; increased borrowing costs, including due to rising interest rates; cash available for distribution to stockholders and our ability to make dividend distributions at expected levels; the availability of external capital on acceptable terms or at all, including due to rising interest rates, changes in our credit ratings and the value of our common stock, bank failures or other events affecting financial institutions; our ability to manage our indebtedness level and covenants in and changes to the terms of such indebtedness; the failure of our tenants, operators, and borrowers to comply with federal, state, and local laws and regulations, including resident health and safety requirements, as well as licensure, certification, and inspection requirements; required regulatory approvals to transfer our senior housing properties; compliance with the Americans with Disabilities Act and fire, safety, and other regulations; laws or regulations prohibiting eviction of our tenants; the requirements of, or changes to, governmental reimbursement programs such as Medicare or Medicaid; legislation to address federal government operations and administrative decisions affecting the Centers for Medicare and Medicaid Services; our participation in the CARES Act Provider Relief Fund and other Covid-related stimulus and relief programs; our ability to maintain our qualification as a REIT; our taxable REIT subsidiaries being subject to corporate level tax; tax imposed on any net income from "prohibited transactions"; changes to U.S. federal income tax laws, and potential deferred and contingent tax liabilities from corporate acquisitions; calculating non-REIT tax earnings and profits distributions; ownership limits in our charter that restrict ownership in our stock; provisions of Maryland law and our charter that could prevent a transaction that may otherwise be in the interest of our stockholders; conflicts of interest between the interests of our stockholders and the interests of holders of Healthpeak OP common units; provisions in the operating agreement of Healthpeak OP and other agreements that may delay or prevent unsolicited acquisitions and other transactions; our status as a holding company of Healthpeak OP; and other risks and uncertainties described from time to time in our Securities and Exchange Commission filings. Except as required by law, we do not undertake, and hereby disclaim, any obligation to update any forward-looking statements, which speak only as of the date on which they are made.

    ADDITIONAL INFORMATION AND WHERE TO FIND IT

    In connection with the proposed transaction, on December 15, 2023, Healthpeak and Physicians Realty Trust filed with the SEC a registration statement on Form S-4 containing a joint proxy statement/prospectus and other documents regarding the proposed transaction. The joint proxy statement/prospectus contains important information about the proposed transaction and related matters. The Form S-4 was declared effective, and each of Healthpeak and Physicians Realty Trust commenced mailing of the joint proxy statement/prospectus included as part of the Form S-4, on January 11, 2024.

    STOCKHOLDERS ARE URGED AND ADVISED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS (INCLUDING ALL AMENDMENTS AND SUPPLEMENTS THERETO) AND OTHER RELEVANT DOCUMENTS FILED WITH THE SEC CAREFULLY BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT HEALTHPEAK, PHYSICIANS REALTY TRUST AND THE PROPOSED TRANSACTION.

    Investors and security holders of Healthpeak and Physicians Realty Trust are able to obtain free copies of the registration statement, the joint proxy statement/prospectus and other relevant documents filed by Healthpeak and Physicians Realty Trust with the SEC through the website maintained by the SEC at www.sec.gov. Copies of the documents filed by Healthpeak with the SEC are also available on Healthpeak's website at www.healthpeak.com, and copies of the documents filed by Physicians Realty Trust with the SEC are available on Physicians Realty Trust's website at www.docreit.com.

    PARTICIPANTS IN THE SOLICITATION

    Healthpeak, Physicians Realty Trust and their respective directors, trustees and executive officers may be deemed to be participants in the solicitation of proxies from Healthpeak's stockholders and Physicians Realty Trust's shareholders in respect of the proposed transaction. Information regarding Healthpeak's directors and executive officers can be found in Healthpeak's definitive proxy statement filed with the SEC on March 17, 2023. Information regarding Physicians Realty Trust's trustees and executive officers can be found in Physicians Realty Trust's definitive proxy statement filed with the SEC on March 23, 2023.

    Additional information regarding the interests of such potential participants is included in the joint proxy statement/prospectus and other relevant documents filed with the SEC in connection with the proposed transaction. These documents are available on the SEC's website and from Healthpeak and Physicians Realty Trust, as applicable, using the sources indicated above.

    NO OFFER OR SOLICITATION

    This communication is for informational purposes only and is neither an offer to purchase, nor a solicitation of an offer to sell, any securities or the solicitation of any vote in any jurisdiction pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

    Healthpeak Properties, Inc.

    Consolidated Balance Sheets

    In thousands, except share and per share data

     

     

    December 31,

    2023

     

    December 31,

    2022

    Assets

     

     

     

    Real estate:

     

     

     

    Buildings and improvements

    $

    13,329,464

     

     

    $

    12,784,078

     

    Development costs and construction in progress

     

    643,217

     

     

     

    760,355

     

    Land and improvements

     

    2,647,633

     

     

     

    2,667,188

     

    Accumulated depreciation and amortization

     

    (3,591,951

    )

     

     

    (3,188,138

    )

    Net real estate

     

    13,028,363

     

     

     

    13,023,483

     

    Loans receivable, net of reserves of $2,830 and $8,280

     

    218,450

     

     

     

    374,832

     

    Investments in and advances to unconsolidated joint ventures

     

    782,853

     

     

     

    706,677

     

    Accounts receivable, net of allowance of $2,282 and $2,399

     

    55,820

     

     

     

    53,436

     

    Cash and cash equivalents

     

    117,635

     

     

     

    72,032

     

    Restricted cash

     

    51,388

     

     

     

    54,802

     

    Intangible assets, net

     

    314,156

     

     

     

    418,061

     

    Assets held for sale, net

     

    117,986

     

     

     

    49,866

     

    Right-of-use asset, net

     

    240,155

     

     

     

    237,318

     

    Other assets, net

     

    772,044

     

     

     

    780,722

     

    Total assets

    $

    15,698,850

     

     

    $

    15,771,229

     

     

     

     

     

    Liabilities and Equity

     

     

     

    Bank line of credit and commercial paper

    $

    720,000

     

     

    $

    995,606

     

    Term loans

     

    496,824

     

     

     

    495,957

     

    Senior unsecured notes

     

    5,403,378

     

     

     

    4,659,451

     

    Mortgage debt

     

    256,097

     

     

     

    346,599

     

    Intangible liabilities, net

     

    127,380

     

     

     

    156,193

     

    Liabilities related to assets held for sale, net

     

    729

     

     

     

    4,070

     

    Lease liability

     

    206,743

     

     

     

    208,515

     

    Accounts payable, accrued liabilities, and other liabilities

     

    657,196

     

     

     

    772,485

     

    Deferred revenue

     

    905,633

     

     

     

    844,076

     

    Total liabilities

     

    8,773,980

     

     

     

    8,482,952

     

     

     

     

     

    Commitments and contingencies

     

     

     

     

     

     

     

    Redeemable noncontrolling interests

     

    48,828

     

     

     

    105,679

     

     

     

     

     

    Common stock, $1.00 par value: 750,000,000 shares authorized; 547,156,311 and 546,641,973 shares issued and outstanding

     

    547,156

     

     

     

    546,642

     

    Additional paid-in capital

     

    10,405,780

     

     

     

    10,349,614

     

    Cumulative dividends in excess of earnings

     

    (4,621,861

    )

     

     

    (4,269,689

    )

    Accumulated other comprehensive income (loss)

     

    19,371

     

     

     

    28,134

     

    Total stockholders' equity

     

    6,350,446

     

     

     

    6,654,701

     

     

     

     

     

    Joint venture partners

     

    310,998

     

     

     

    327,721

     

    Non-managing member unitholders

     

    214,598

     

     

     

    200,176

     

    Total noncontrolling interests

     

    525,596

     

     

     

    527,897

     

     

     

     

     

    Total equity

     

    6,876,042

     

     

     

    7,182,598

     

     

     

     

     

    Total liabilities and equity

    $

    15,698,850

     

     

    $

    15,771,229

     

    Healthpeak Properties, Inc.

    Consolidated Statements of Operations

    In thousands, except per share data

     

     

    Three Months Ended

    December 31,

     

    Year Ended

    December 31,

     

    2023

     

    2022

     

    2023

     

    2022

    Revenues:

     

     

     

     

     

    Rental and related revenues

    $

    412,332

     

     

    $

    392,245

     

     

    $

    1,631,805

     

     

    $

    1,541,775

     

    Resident fees and services

     

    136,341

     

     

     

    125,873

     

     

     

    527,417

     

     

     

    494,935

     

    Interest income

     

    4,979

     

     

     

    6,350

     

     

     

    21,781

     

     

     

    23,300

     

    Income from direct financing leases

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    1,168

     

    Total revenues

     

    553,652

     

     

     

    524,468

     

     

     

    2,181,003

     

     

     

    2,061,178

     

     

     

     

     

     

     

     

     

    Costs and expenses:

     

     

     

     

     

     

     

    Interest expense

     

    52,784

     

     

     

    49,413

     

     

     

    200,331

     

     

     

    172,944

     

    Depreciation and amortization

     

    188,544

     

     

     

    179,157

     

     

     

    749,901

     

     

     

    710,569

     

    Operating

     

    224,401

     

     

     

    220,492

     

     

     

    902,060

     

     

     

    862,991

     

    General and administrative

     

    21,556

     

     

     

    57,872

     

     

     

    95,132

     

     

     

    131,033

     

    Transaction and merger-related costs

     

    14,417

     

     

     

    3,217

     

     

     

    17,515

     

     

     

    4,853

     

    Impairments and loan loss reserves (recoveries), net

     

    (5,445

    )

     

     

    3,326

     

     

     

    (5,601

    )

     

     

    7,004

     

    Total costs and expenses

     

    496,257

     

     

     

    513,477

     

     

     

    1,959,338

     

     

     

    1,889,394

     

    Other income (expense):

     

     

     

     

     

     

     

    Gain (loss) on sales of real estate, net

     

    —

     

     

     

    (969

    )

     

     

    86,463

     

     

     

    9,078

     

    Other income (expense), net

     

    2,600

     

     

     

    (587

    )

     

     

    6,808

     

     

     

    326,268

     

    Total other income (expense), net

     

    2,600

     

     

     

    (1,556

    )

     

     

    93,271

     

     

     

    335,346

     

     

     

     

     

     

     

     

     

    Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures

     

    59,995

     

     

     

    9,435

     

     

     

    314,936

     

     

     

    507,130

     

    Income tax benefit (expense)

     

    11,842

     

     

     

    650

     

     

     

    9,617

     

     

     

    4,425

     

    Equity income (loss) from unconsolidated joint ventures

     

    3,558

     

     

     

    (156

    )

     

     

    10,204

     

     

     

    1,985

     

    Income (loss) from continuing operations

     

    75,395

     

     

     

    9,929

     

     

     

    334,757

     

     

     

    513,540

     

     

     

     

     

     

     

     

     

    Income (loss) from discontinued operations

     

    —

     

     

     

    873

     

     

     

    —

     

     

     

    2,884

     

     

     

     

     

     

     

     

     

    Net income (loss)

     

    75,395

     

     

     

    10,802

     

     

     

    334,757

     

     

     

    516,424

     

    Noncontrolling interests' share in continuing operations

     

    (4,451

    )

     

     

    (4,274

    )

     

     

    (28,748

    )

     

     

    (15,975

    )

    Net income (loss) attributable to Healthpeak Properties, Inc.

     

    70,944

     

     

     

    6,528

     

     

     

    306,009

     

     

     

    500,449

     

    Participating securities' share in earnings

     

    (157

    )

     

     

    (140

    )

     

     

    (1,725

    )

     

     

    (2,657

    )

    Net income (loss) applicable to common shares

    $

    70,787

     

     

    $

    6,388

     

     

    $

    304,284

     

     

    $

    497,792

     

     

     

     

     

     

     

     

     

    Basic earnings (loss) per common share:

     

     

     

     

     

     

     

    Continuing operations

    $

    0.13

     

     

    $

    0.01

     

     

    $

    0.56

     

     

    $

    0.92

     

    Discontinued operations

     

    —

     

     

     

    0.00

     

     

     

    —

     

     

     

    0.00

     

    Net income (loss) applicable to common shares

    $

    0.13

     

     

    $

    0.01

     

     

    $

    0.56

     

     

    $

    0.92

     

     

     

     

     

     

     

     

     

    Diluted earnings (loss) per common share:

     

     

     

     

     

     

     

    Continuing operations

    $

    0.13

     

     

    $

    0.01

     

     

    $

    0.56

     

     

    $

    0.92

     

    Discontinued operations

     

    —

     

     

     

    0.00

     

     

     

    —

     

     

     

    0.00

     

    Net income (loss) applicable to common shares

    $

    0.13

     

     

    $

    0.01

     

     

    $

    0.56

     

     

    $

    0.92

     

     

     

     

     

     

     

     

     

    Weighted average shares outstanding:

     

     

     

     

     

     

     

    Basic

     

    547,091

     

     

     

    537,992

     

     

     

    547,006

     

     

     

    538,809

     

    Diluted

     

    547,361

     

     

     

    538,396

     

     

     

    547,275

     

     

     

    539,147

     

    Healthpeak Properties, Inc.

    Funds From Operations

    In thousands, except per share data

     

     

     

     

     

     

     

    Three Months Ended

    December 31,

     

    Year Ended

    December 31,

     

     

    2023

     

    2022

     

    2023

     

    2022

    Net income (loss) applicable to common shares

     

    $

    70,787

     

     

    $

    6,388

     

     

    $

    304,284

     

     

    $

    497,792

     

    Real estate related depreciation and amortization

     

     

    188,544

     

     

     

    179,157

     

     

     

    749,901

     

     

     

    710,569

     

    Healthpeak's share of real estate related depreciation and amortization from unconsolidated joint ventures

     

     

    6,723

     

     

     

    8,642

     

     

     

    24,800

     

     

     

    27,691

     

    Noncontrolling interests' share of real estate related depreciation and amortization

     

     

    (4,610

    )

     

     

    (4,709

    )

     

     

    (18,654

    )

     

     

    (19,201

    )

    Loss (gain) on sales of depreciable real estate, net

     

     

    —

     

     

     

    986

     

     

     

    (86,463

    )

     

     

    (10,422

    )

    Healthpeak's share of loss (gain) on sales of depreciable real estate, net, from unconsolidated joint ventures

     

     

    —

     

     

     

    45

     

     

     

    —

     

     

     

    134

     

    Noncontrolling interests' share of gain (loss) on sales of depreciable real estate, net

     

     

    —

     

     

     

    —

     

     

     

    11,546

     

     

     

    12

     

    Loss (gain) upon change of control, net(1)

     

     

    —

     

     

     

    —

     

     

     

    (234

    )

     

     

    (311,438

    )

    Taxes associated with real estate dispositions

     

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    29

     

    Nareit FFO applicable to common shares

     

     

    261,444

     

     

     

    190,509

     

     

     

    985,180

     

     

     

    895,166

     

    Distributions on dilutive convertible units and other

     

     

    2,366

     

     

     

    1,649

     

     

     

    9,394

     

     

     

    9,407

     

    Diluted Nareit FFO applicable to common shares

     

    $

    263,810

     

     

    $

    192,158

     

     

    $

    994,574

     

     

    $

    904,573

     

    Diluted Nareit FFO per common share

     

    $

    0.48

     

     

    $

    0.35

     

     

    $

    1.79

     

     

    $

    1.66

     

    Weighted average shares outstanding - diluted Nareit FFO

     

     

    554,635

     

     

     

    543,879

     

     

     

    554,559

     

     

     

    546,462

     

    Impact of adjustments to Nareit FFO:

     

     

     

     

     

     

     

     

    Transaction and merger-related items(2)

     

    $

    10,842

     

     

    $

    3,215

     

     

    $

    13,835

     

     

    $

    4,788

     

    Other impairments (recoveries) and other losses (gains), net(3)

     

     

    (4,407

    )

     

     

    9,702

     

     

     

    (3,850

    )

     

     

    3,829

     

    Restructuring and severance-related charges(4)

     

     

    —

     

     

     

    32,749

     

     

     

    1,368

     

     

     

    32,749

     

    Casualty-related charges (recoveries), net(5)

     

     

    (3,424

    )

     

     

    298

     

     

     

    (4,033

    )

     

     

    4,401

     

    Recognition (reversal) of valuation allowance on deferred tax assets(6)

     

     

    (14,194

    )

     

     

    —

     

     

     

    (14,194

    )

     

     

    —

     

    Total adjustments

     

     

    (11,183

    )

     

     

    45,964

     

     

     

    (6,874

    )

     

     

    45,767

     

    FFO as Adjusted applicable to common shares

     

     

    250,261

     

     

     

    236,473

     

     

     

    978,306

     

     

     

    940,933

     

    Distributions on dilutive convertible units and other

     

     

    2,378

     

     

     

    2,271

     

     

     

    9,402

     

     

     

    9,326

     

    Diluted FFO as Adjusted applicable to common shares

     

    $

    252,639

     

     

    $

    238,744

     

     

    $

    987,708

     

     

    $

    950,259

     

    Diluted FFO as Adjusted per common share

     

    $

    0.46

     

     

    $

    0.44

     

     

    $

    1.78

     

     

    $

    1.74

     

    Weighted average shares outstanding - diluted FFO as Adjusted

     

     

    554,635

     

     

     

    545,704

     

     

     

    554,559

     

     

     

    546,462

     

    _______________________________________

    (1)

    The year ended December 31, 2022 includes a gain upon change of control related to the sale of a 30% interest to a sovereign wealth fund and deconsolidation of seven previously consolidated lab buildings in South San Francisco, California. The gain upon change of control is included in other income (expense), net in the Consolidated Statements of Operations.

    (2)

    The three months and year ended December 31, 2023 include costs related to the proposed merger with Physicians Realty Trust, which are primarily comprised of legal, accounting, tax, and other costs that were incurred prior to year-end, partially offset by termination fee income associated with Graphite Bio, Inc., for which the lease terms have been modified to accelerate expiration of the lease to December 2024. Termination fee income is included in rental and related revenues on the Consolidated Statements of Operations.

    (3)

    The three months and year ended December 31, 2022 include $7 million of charges incurred in connection with the downsizing of the Company's corporate headquarters in Denver, Colorado, which are included in general and administrative expenses in the Consolidated Statements of Operations. The year ended December 31, 2022 also includes the following, which are included in other income (expense), net in the Consolidated Statements of Operations: (i) $14 million of expenses incurred for tenant relocation and other costs associated with the demolition of an outpatient medical building and (ii) a $23 million gain on sale of a hospital under a direct financing lease. The three months and years ended December 31, 2023 and 2022 include reserves and (recoveries) for expected loan losses recognized in impairments and loan loss reserves (recoveries), net in the Consolidated Statements of Operations.

    (4)

    The three months and year ended December 31, 2022 include $32 million of severance-related charges associated with the departures of our former Chief Executive Officer and former Chief Legal Officer and General Counsel in the fourth quarter of 2022. These expenses are included in general and administrative expenses in the Consolidated Statements of Operations.

    (5)

    Casualty-related charges (recoveries), net are recognized in other income (expense), net and equity income (loss) from unconsolidated joint ventures in the Consolidated Statements of Operations.

    (6)

    In conjunction with classifying the assets related to the Callan Ridge JV as held for sale as of December 31, 2023, we concluded it was more likely than not that we would realize the future value of certain deferred tax assets generated by the net operating losses of taxable REIT subsidiaries. Accordingly, during the three months and year ended December 31, 2023, we recognized the reversal of a portion of the associated valuation allowance and recognized a corresponding income tax benefit.

    Healthpeak Properties, Inc.

    Adjusted Funds From Operations

    In thousands

     

     

     

     

     

     

     

    Three Months Ended

    December 31,

     

    Year Ended

    December 31,

     

     

    2023

     

    2022

     

    2023

     

    2022

    FFO as Adjusted applicable to common shares

    $

    250,261

     

     

    $

    236,473

     

     

    $

    978,306

     

     

    $

    940,933

     

    Stock-based compensation amortization expense

     

    3,513

     

     

     

    1,903

     

     

     

    14,480

     

     

     

    16,537

     

    Amortization of deferred financing costs

     

    3,088

     

     

     

    2,812

     

     

     

    11,916

     

     

     

    10,881

     

    Straight-line rents(1)

     

    (1,677

    )

     

     

    (12,346

    )

     

     

    (14,387

    )

     

     

    (49,183

    )

    AFFO capital expenditures

     

    (47,332

    )

     

     

    (33,407

    )

     

     

    (113,596

    )

     

     

    (108,510

    )

    Deferred income taxes

     

    117

     

     

     

    (355

    )

     

     

    (816

    )

     

     

    (4,096

    )

    Amortization of above (below) market lease intangibles, net

     

    (5,525

    )

     

     

    (5,851

    )

     

     

    (25,791

    )

     

     

    (23,380

    )

    Other AFFO adjustments

     

    (7,486

    )

     

     

    3,536

     

     

     

    (9,335

    )

     

     

    520

     

    AFFO applicable to common shares

     

    194,959

     

     

     

    192,765

     

     

     

    840,777

     

     

     

    783,702

     

    Distributions on dilutive convertible units and other

     

    1,663

     

     

     

    1,649

     

     

     

    6,581

     

     

     

    6,594

     

    Diluted AFFO applicable to common shares

    $

    196,622

     

     

    $

    194,414

     

     

    $

    847,358

     

     

    $

    790,296

     

    Diluted AFFO per common share

    $

    0.36

     

     

    $

    0.36

     

     

    $

    1.53

     

     

    $

    1.45

     

    Weighted average shares outstanding - diluted AFFO

     

    552,810

     

     

     

    543,879

     

     

     

    552,734

     

     

     

    544,637

     

    _______________________________________

    (1)

    The year ended December 31, 2023 includes an $8.7 million write-off of straight-line rent receivable associated with Sorrento Therapeutics, Inc., which commenced voluntary reorganization proceedings under Chapter 11 of the U.S. Bankruptcy Code. This activity is reflected as a reduction of rental and related revenues in the Consolidated Statements of Operations.

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240208718917/en/

    Get the next $BMY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BMY
    $PEAK

    CompanyDatePrice TargetRatingAnalyst
    Bristol-Myers Squibb Company
    $BMY
    4/22/2025$55.00Neutral
    Cantor Fitzgerald
    Bristol-Myers Squibb Company
    $BMY
    4/22/2025Overweight
    Piper Sandler
    Bristol-Myers Squibb Company
    $BMY
    12/16/2024$70.00Hold → Buy
    Jefferies
    Bristol-Myers Squibb Company
    $BMY
    12/10/2024$63.00Neutral
    BofA Securities
    Bristol-Myers Squibb Company
    $BMY
    11/15/2024Peer Perform
    Wolfe Research
    Bristol-Myers Squibb Company
    $BMY
    11/13/2024Neutral → Outperform
    Daiwa Securities
    Bristol-Myers Squibb Company
    $BMY
    11/12/2024$73.00Market Perform → Outperform
    Leerink Partners
    Bristol-Myers Squibb Company
    $BMY
    10/25/2024$75.00 → $55.00Buy → Neutral
    Citigroup
    More analyst ratings

    $BMY
    $PEAK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Bristol-Myers with a new price target

      Cantor Fitzgerald initiated coverage of Bristol-Myers with a rating of Neutral and set a new price target of $55.00

      4/22/25 8:00:39 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Bristol-Myers

      Piper Sandler initiated coverage of Bristol-Myers with a rating of Overweight

      4/22/25 7:30:03 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bristol-Myers upgraded by Jefferies with a new price target

      Jefferies upgraded Bristol-Myers from Hold to Buy and set a new price target of $70.00

      12/16/24 6:45:40 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMY
    $PEAK
    SEC Filings

    See more
    • Bristol-Myers Squibb Company filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)

      5/7/25 5:04:09 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Bristol-Myers Squibb Company

      10-Q - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)

      4/24/25 11:45:34 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bristol-Myers Squibb Company filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)

      4/24/25 7:11:41 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMY
    $PEAK
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $BMY
    $PEAK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Bristol Myers Squibb to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

      Bristol Myers Squibb (NYSE:BMY) today announced that the company will participate in the Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday, June 11, 2025. The company will take part in a fireside chat beginning at 10:00 a.m. ET. Investors and the general public are invited to listen to the session by visiting http://investor.bms.com. An archived edition of the session will be available following its conclusion. About Bristol Myers Squibb: Transforming Patients' Lives Through Science At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define wh

      5/28/25 6:59:00 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications

      Opdivo is the first and only PD-1 inhibitor approved for subcutaneous (SC) use in the European Union Approval is based on results from the Phase 3 CheckMate -67T clinical trial which demonstrated noninferiority in the co-primary endpoints of Cavgd28 and Cminss, and consistent efficacy in the secondary endpoint of overall response rate, for the subcutaneous formulation of Opdivo (Opdivo SC) vs. its intravenous formulation (IV Opdivo) Bristol Myers Squibb (NYSE:BMY) today announced that the European Commission (EC) has approved a new Opdivo® (nivolumab) formulation associated with a new route of administration (subcutaneous use [SC]), a new pharmaceutical form (solution for injection) and

      5/28/25 6:55:00 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bristol Myers Squibb to Present Data at ASCO® 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline

      Bristol Myers Squibb (NYSE:BMY) today announced the presentation of data across its oncology portfolio and pipeline at the 2025 American Society of Clinical Oncology (ASCO®) Annual Meeting to be held May 30-June 3 in Chicago, Illinois. Data from more than 80 company-sponsored studies, investigator-sponsored studies, and collaborations showcase results spanning more than 20 cancer types. "Bristol Myers Squibb is advancing novel approaches to address high unmet needs in cancer and at this year's ASCO meeting, we are highlighting data across a range of assets, including our targeted therapy pipeline, and new data that support the use of our portfolio in earlier lines of treatment, enhancing o

      5/22/25 5:05:00 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Healthpeak Properties Inc. (Amendment)

      SC 13G/A - HEALTHPEAK PROPERTIES, INC. (0000765880) (Subject)

      2/13/24 5:06:13 PM ET
      $PEAK
      Real Estate Investment Trusts
      Real Estate
    • SEC Form SC 13G/A filed by Healthpeak Properties Inc. (Amendment)

      SC 13G/A - HEALTHPEAK PROPERTIES, INC. (0000765880) (Subject)

      1/30/24 11:08:50 AM ET
      $PEAK
      Real Estate Investment Trusts
      Real Estate
    • SEC Form SC 13G/A filed by Bristol-Myers Squibb Company (Amendment)

      SC 13G/A - BRISTOL MYERS SQUIBB CO (0000014272) (Subject)

      2/9/23 11:12:40 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMY
    $PEAK
    Leadership Updates

    Live Leadership Updates

    See more
    • Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer

      Gallman's Appointment is Effective Immediately Sandra Leung, Executive Vice President, General Counsel Retires After 33 Years of Service Bristol Myers Squibb (NYSE:BMY) today announced the appointment of Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer, effective immediately. Gallman succeeds Sandra (Sandy) Leung, who has chosen to retire after an extraordinary 33-year career at the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250506937441/en/Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer Gallman, an accomplished leade

      5/6/25 6:59:00 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cardurion Pharmaceuticals Appoints Karen Lewis as Chief People Officer

      Cardurion Pharmaceuticals, Inc. ("Cardurion"), a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of cardiovascular diseases, today announced that Karen Lewis has joined the company as Chief People Officer. She joins Cardurion with more than 25 years of experience in human resources helping to build organizations and develop programs that support companies at various stages of growth. She most recently was Chief People Officer at Apellis Pharmaceuticals (NASDAQ:APLS) during a period of rapid growth, and previously held leadership roles in human resources at Biogen (NASDAQ:BIIB) and Bristol-Myers Squibb (NYSE:BMY). "We're delighted

      3/20/25 8:00:00 AM ET
      $APLS
      $BIIB
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • LivaNova Appoints Natalia Kozmina as Chief Human Resources Officer

      LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that Natalia Kozmina is joining the Company as Chief Human Resources Officer (CHRO), effective January 14. Kozmina will lead global human resources, serve on the Executive Leadership Team, and report to Vladimir Makatsaria, Chief Executive Officer. "Natalia has a deep background in the medtech and life sciences sectors and is a proven enterprise and executive leader in human resources management," Makatsaria said. "I look forward to collaborating with Natalia to further strengthen our organizational culture and build a thriving environment at LivaNova." Kozmina most recently served as Executive Vice

      1/6/25 9:00:00 AM ET
      $ABT
      $BMY
      $IRM
      $LIVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Real Estate Investment Trusts
      Real Estate

    $BMY
    $PEAK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $BMY
    $PEAK
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more

    $BMY
    $PEAK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $BMY
    $PEAK
    Financials

    Live finance-specific insights

    See more
    • President, RayzeBio Org. Hickey Benjamin sold $3,702 worth of shares (97 units at $38.01) (SEC Form 4)

      4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

      5/13/25 7:03:35 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by EVP, Chief Commercial Officer Lenkowsky Adam

      4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

      5/5/25 5:41:48 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP,Chief Med.Offr.,Drug Dev. Hirawat Samit bought $202,215 worth of shares (4,250 units at $47.58), increasing direct ownership by 5% to 83,513 units (SEC Form 4)

      4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

      4/29/25 6:14:13 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • September 26, 2024 - FDA Approves Drug with New Mechanism of Action for Treatment of Schizophrenia

      For Immediate Release: September 26, 2024 Today, the U.S. Food and Drug Administration approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. It is the first antipsychotic drug approved to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors, which has long been the standard of care.   “Schizophrenia is a leading

      9/26/24 6:42:20 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • June 14, 2024 - FDA Roundup: June 14, 2024

      For Immediate Release: June 14, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a proposed exemption for certain cottage cheese products from the requirements of the Food Traceability Rule. The proposal would exempt Grade “A” cottage cheese that appears on the Interstate Milk Shippers List from the requirements of the r

      6/14/24 3:54:45 PM ET
      $MMSI
      $BMY
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • March 8, 2024 - FDA Roundup: March 8, 2024

      For Immediate Release: March 08, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced proposed new regulations to provide animal drug sponsors with predictable requirements for the labeling of prescription and over-the-counter new animal drugs, as well as new animal drugs for use in animal feeds. The proposed content and

      3/8/24 3:26:46 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP,Chief Med.Offr.,Drug Dev. Hirawat Samit bought $202,215 worth of shares (4,250 units at $47.58), increasing direct ownership by 5% to 83,513 units (SEC Form 4)

      4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

      4/29/25 6:14:13 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Boerner Christopher S. bought $110,096 worth of shares (2,000 units at $55.05), increasing direct ownership by 2% to 104,626 units (SEC Form 4)

      4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

      2/21/25 7:09:34 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP,Chief Med.Offr.,Drug Dev. Hirawat Samit bought $100,000 worth of shares (1,823 units at $54.84), increasing direct ownership by 3% to 63,932 units (SEC Form 4)

      4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

      2/19/25 7:19:54 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bristol Myers Squibb Reports First Quarter Financial Results for 2025

      Results Reflect Continued Growth Portfolio Momentum and Disciplined Execution   First quarter revenues were $11.2 billion, -6% (-4% Ex-FX) Growth Portfolio revenues were $5.6 billion, +16% (+18% Ex-FX) GAAP EPS was $1.20 and non-GAAP EPS was $1.80 Raising 2025 revenue guidance to a range of ~$45.8 billion to $46.8 billion; Increasing non-GAAP EPS range to $6.70 to $7.00 Bristol Myers Squibb (NYSE:BMY) today reports results for the first quarter of 2025. "Our strong execution in the first quarter drove continued momentum across our Growth Portfolio and meaningful progress in the pipeline," said Christopher Boerner, Ph.D., board chair and chief executive officer, Bristol Myers Sq

      4/24/25 6:59:00 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bristol Myers Squibb to Report Results for First Quarter 2025 on April 24, 2025

      Bristol Myers Squibb (NYSE:BMY) will announce results for the first quarter of 2025 on Thursday, April 24, 2025. Company executives will review financial results with the investment community during a conference call beginning at 8:00 a.m. ET. Investors and the general public are invited to listen to a live webcast of the call at http://investor.bms.com. Materials related to the call will be available at http://investor.bms.com prior to the start of the conference call. A replay of the webcast will be available at http://investor.bms.com approximately three hours after the conference call concludes. About Bristol Myers Squibb Bristol Myers Squibb is a global biopharmaceutical company wh

      3/13/25 6:59:00 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bristol Myers Squibb Announces Dividend

      Bristol Myers Squibb (NYSE:BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-two cents ($0.62) per share on the $0.10 par value common stock of the company. The dividend is payable on May 1, 2025, to stockholders of record at the close of business on April 4, 2025. In addition, the Board of Directors has declared a quarterly dividend of fifty cents ($0.50) per share on the company's $2.00 convertible preferred stock, payable on June 2, 2025, to stockholders of record at the close of business on May 6, 2025. About Bristol Myers Squibb Company Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop, and d

      3/3/25 4:16:00 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care